OR WAIT null SECS
© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
October 27, 2021
Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.
The phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in children 5 to 11 years of age.
October 26, 2021
Seglentis’ co-crystal formulation targets four complementary pain relief mechanisms.
October 25, 2021
Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
October 22, 2021
Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.
Oncopeptides will close down its business units in the United States and Europe to focus exclusively on being a Sweden-based R&D company.
Developed by Regeneron Pharmaceuticals and Sanofi, Dupixent reduced severe asthma attacks and improved lung function in children 6 to 11 years.
October 21, 2021
A phase 3 trial of Pfizer and BioNTech’s COVID-19 vaccine booster demonstrates an efficacy rate of 95.6%.
Tecentriq is the first cancer immunotherapy available for adjuvant treatment of non-small cell lung cancer (NSCLC).
October 20, 2021
Dr. Reddy’s received FDA approval for two strengths of lenalidomide for the treatment of patients with multiple myeloma.